BRIEF published on 09/11/2024 at 07:35, 1 year 8 months ago Medincell établit un nouveau contrat de liquidité avec Rothschild Martin Maurel Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Actions Ordinaires Medincell
BRIEF published on 09/11/2024 at 07:35, 1 year 8 months ago Medincell establishes a new liquidity contract with Rothschild Martin Maurel Common Shares Euronext Paris Liquidity Contract Rothschild Martin Maurel Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 1 year 8 months ago Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité Medincell confie son Contrat de liquidité à ROTHSCHILD MARTIN MAUREL pour animer ses actions sur Euronext Paris, conformément à la réglementation en vigueur Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Réglementation Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 1 year 8 months ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01 Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
BRIEF published on 09/05/2024 at 07:35, 1 year 8 months ago Medincell : avancées prometteuses pour l'Olanzapine injectable Schizophrénie Phase 3 Medincell Olanzapine Teva Pharmaceuticals
BRIEF published on 09/05/2024 at 07:35, 1 year 8 months ago Medincell: Promising advances for injectable Olanzapine Schizophrenia Phase 3 Medincell Olanzapine Teva Pharmaceuticals
PRESS RELEASE published on 09/05/2024 at 07:30, 1 year 8 months ago Informations privilégiées / Autres communiqués Teva, partenaire de Medincell, annonce des avancées importantes dans l'essai clinique pivot de phase 3 de l'Olanzapine injectable à durée d’action prolongée, avec un taux élevé d'injections réalisées et des résultats positifs attendus Schizophrénie Essai Clinique Medincell Olanzapine Teva
PRESS RELEASE published on 09/05/2024 at 07:30, 1 year 8 months ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 08/20/2024 at 17:52, 1 year 8 months ago Modalités de participation à l’Assemblée Générale de Medincell Actionnaires Assemblée Générale Vote À Distance Medincell Videoconference
BRIEF published on 08/20/2024 at 17:52, 1 year 8 months ago Terms of participation in the Medincell General Meeting Shareholders General Assembly Remote Voting Medincell Videoconference
Published on 05/13/2026 at 00:00, 1 hour 25 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 1 hour 50 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 3 hours 30 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 3 hours 43 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 10 hours 55 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 23:47, 1 hour 37 minutes ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 2 hours 59 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 5 hours 3 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 5 hours 50 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 5 hours 50 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:15, 7 hours 10 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 7 hours 10 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 7 hours 15 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 7 hours 15 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 7 hours 35 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
